XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - (Tables)
6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2021202020212020
Medicare19 %18 %19 %22 %
Medicare Advantage13 %*12 %11 %
Blue Shield11 %11 %11 %12 %
Janssen (SIMPONI®)
*23 %*11 %
*Less than 10%.
 Accounts Receivable
 June 30, 2021December 31, 2020
 
Blue Shield16 %11 %
United Healthcare13 %*
Janssen (SIMPONI®)
*35 %
*Less than 10%.
Disaggregation of Revenue The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended June 30,Six Months Ended June 30,
 2021202020212020
Revenue:
Healthcare insurers$7,381 $4,138 $13,408 $10,200 
Government2,394 1,807 4,403 4,052 
Client(1)2,427 746 4,392 1,828 
Other(2)270 206 556 401 
Janssen (SIMPONI®)
300 2,051 600 2,051 
Total revenue$12,772 $8,948 $23,359 $18,532 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay that is immaterial.
Schedule of Restricted Cash and Cash Equivalents Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands): 
 June 30, 2021December 31, 2020
 
Cash and cash equivalents$112,576 $57,448 
Restricted cash100 100 
$112,676 $57,548 
Schedule of Cash and Cash Equivalents Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands): 
 June 30, 2021December 31, 2020
 
Cash and cash equivalents$112,576 $57,448 
Restricted cash100 100 
$112,676 $57,548 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):
 
 Three Months Ended June 30,Six Months Ended June 30,
 2021202020212020
Warrants to purchase common stock426,827 426,827 426,827 426,827 
Common stock options2,123,617 1,677,000 2,123,617 1,677,000 
Restricted stock units375,525 — 375,525 — 
Employee stock purchase plan12,525 10,259 12,525 10,259 
Total2,938,494 2,114,086 2,938,494 2,114,086